目的:综述天然药物基于核转录因子κB(NF-κB)信号通路抗类风湿性关节炎的机制,为抗类风湿性关节炎的新药研发提供参考。方法:以"NF-κB""天然药物""中药""民族药""类风湿性关节炎"&...目的:综述天然药物基于核转录因子κB(NF-κB)信号通路抗类风湿性关节炎的机制,为抗类风湿性关节炎的新药研发提供参考。方法:以"NF-κB""天然药物""中药""民族药""类风湿性关节炎""Natural medicine""Traditional Chinese medicine""Ethnomedicine""Rheumatoid arthritis"等为关键词,组合查询2013年1月-2018年11月中国知网、万方数据、维普网、PubMed、Elservier等数据库中的相关文献,从组方制剂、单味药材提取物、中药活性成分三个方面总结天然药物基于NF-κB信号通路抗类风湿性关节炎的实验研究进展。结果与结论:共检索到相关文献645篇,其中有效文献54篇。组方制剂如双藤痹痛酊、仙方活命饮、二妙散、桂枝芍药知母汤、龙钻通痹方、金乌健骨汤,单味药材如龙须藤、类叶牡丹、黑骨藤、天麻,中药活性成分如雷公藤红素、青藤碱、姜黄素、黄芩苷、芍药苷等均能通过抑制NF-κB信号通路中相关蛋白[如NF-κB蛋白、NF-κB抑制蛋白(IκB)]和酶[如IκB激酶(IKK)]的表达,阻断NF-κB信号通路的激活,从而抑制肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)、IL-6等多种促炎细胞因子的生成,改善炎症反应,进而抑制类风湿性关节炎的病理变化。由于天然药物成分复杂,其药理活性一般是多种活性成分协同作用的结果,建议在后续的研究中,应进一步通过实验明确天然药物基于NF-κB信号通路抗类风湿性关节炎的作用机制及药效基础,为研发抗类风湿性关节炎新型药物提供新的思路与实验依据。展开更多
OBJECTIVE To investigate gene mutations of epidermal growth factor receptor （EGFR） and K-RAS （Kirsten rat sarcoma viral oncogene） in Chinese patients with non-small cell lung cancer （NSCLC）, and study the correl...OBJECTIVE To investigate gene mutations of epidermal growth factor receptor （EGFR） and K-RAS （Kirsten rat sarcoma viral oncogene） in Chinese patients with non-small cell lung cancer （NSCLC）, and study the correlation with its protein expression and its clinical significance on gefitinib.METHODS Detect the EGFR and K-RAS gene mutations status by gene sequencing and use the method of immunohistochemistry to detect EGFR and K-RAS protein expression.RESULTS The frequency of EGFR mutations was 33%, mainly located in exon 19 and exon 21. The frequency of K-RAS mutations was 5.5%, mainly located in codon 12. There was no case which both had EGFR and K-RAS mutations, suggesting a mutually exclusive relationship between the two. EGFR mutations are more common in adenocarcinomas （particularly those with bronchioloalveolar features）, nonsmokers and females. 16% were detected EGFR positive expression and had no correlation with EGFR mutation （P 〉 0.05）, but had significant correlation with mutation in exon 19 （P 〈 0.05）. The frequency of K-RAS positive expression was 52.5% and had no correlation with K-RAS mutation （P 〉 0.05）. Twelve （8 cases were protein-negative） out of 15 gefitinib-treated NSCLC patients with disease control carry EGFR mutations.CONCLUSION EGFR protein expression has some correlation with exon 19 mutations. Combined detection of EGFR and K-RAS gene mutations can help clinicians to choose patients who may benefit from EGFR tyrosine kinase inhibitor （EGFR-TKI） and to predict the response and prognosis of gefitinib.展开更多
文摘目的:综述天然药物基于核转录因子κB(NF-κB)信号通路抗类风湿性关节炎的机制,为抗类风湿性关节炎的新药研发提供参考。方法:以"NF-κB""天然药物""中药""民族药""类风湿性关节炎""Natural medicine""Traditional Chinese medicine""Ethnomedicine""Rheumatoid arthritis"等为关键词,组合查询2013年1月-2018年11月中国知网、万方数据、维普网、PubMed、Elservier等数据库中的相关文献,从组方制剂、单味药材提取物、中药活性成分三个方面总结天然药物基于NF-κB信号通路抗类风湿性关节炎的实验研究进展。结果与结论:共检索到相关文献645篇,其中有效文献54篇。组方制剂如双藤痹痛酊、仙方活命饮、二妙散、桂枝芍药知母汤、龙钻通痹方、金乌健骨汤,单味药材如龙须藤、类叶牡丹、黑骨藤、天麻,中药活性成分如雷公藤红素、青藤碱、姜黄素、黄芩苷、芍药苷等均能通过抑制NF-κB信号通路中相关蛋白[如NF-κB蛋白、NF-κB抑制蛋白(IκB)]和酶[如IκB激酶(IKK)]的表达,阻断NF-κB信号通路的激活,从而抑制肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)、IL-6等多种促炎细胞因子的生成,改善炎症反应,进而抑制类风湿性关节炎的病理变化。由于天然药物成分复杂,其药理活性一般是多种活性成分协同作用的结果,建议在后续的研究中,应进一步通过实验明确天然药物基于NF-κB信号通路抗类风湿性关节炎的作用机制及药效基础,为研发抗类风湿性关节炎新型药物提供新的思路与实验依据。
文摘OBJECTIVE To investigate gene mutations of epidermal growth factor receptor （EGFR） and K-RAS （Kirsten rat sarcoma viral oncogene） in Chinese patients with non-small cell lung cancer （NSCLC）, and study the correlation with its protein expression and its clinical significance on gefitinib.METHODS Detect the EGFR and K-RAS gene mutations status by gene sequencing and use the method of immunohistochemistry to detect EGFR and K-RAS protein expression.RESULTS The frequency of EGFR mutations was 33%, mainly located in exon 19 and exon 21. The frequency of K-RAS mutations was 5.5%, mainly located in codon 12. There was no case which both had EGFR and K-RAS mutations, suggesting a mutually exclusive relationship between the two. EGFR mutations are more common in adenocarcinomas （particularly those with bronchioloalveolar features）, nonsmokers and females. 16% were detected EGFR positive expression and had no correlation with EGFR mutation （P 〉 0.05）, but had significant correlation with mutation in exon 19 （P 〈 0.05）. The frequency of K-RAS positive expression was 52.5% and had no correlation with K-RAS mutation （P 〉 0.05）. Twelve （8 cases were protein-negative） out of 15 gefitinib-treated NSCLC patients with disease control carry EGFR mutations.CONCLUSION EGFR protein expression has some correlation with exon 19 mutations. Combined detection of EGFR and K-RAS gene mutations can help clinicians to choose patients who may benefit from EGFR tyrosine kinase inhibitor （EGFR-TKI） and to predict the response and prognosis of gefitinib.
